

## **LISTING OF THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Original) A pharmaceutical composition comprising:

- a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one estrogen or prodrug thereof; and
- c) a therapeutically effective amount of at least one selective estrogen receptor modulator or prodrug thereof, wherein said modulator is a different compound from said estrogen and said modulator is not a benzothiophene derivative, a phenylindole derivative, a naphthalene derivative, an isoquinoline derivative or an enantiomeric mixture of 3-phenylquinoline derivatives, 3-phenylthiochroman derivatives, and 3-phenylchroman derivatives having more than 10 % of the enantiomer of 2R configuration.

Claim 2 (Original) A pharmaceutical composition comprising:

- a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one estrogen or prodrug thereof;
- c) a therapeutically effective amount of at least one selective estrogen receptor modulator or prodrug thereof, wherein said modulator is a different compound from said estrogen; and
- (d) a therapeutically effective amount of at least one additional agent selected from the group consisting of bisphosphonate, progestogen, an androgenic agent, testosterone, dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3 $\beta$ ,17 $\beta$ -diol, 4-androstene-3,17-dione, and a prodrug of any of the foregoing additional agents.


Claim 3 (Original) The pharmaceutical composition of claim 1, wherein the selective estrogen receptor modulator has a molecular formula with the following features:

a) two aromatic rings spaced by 1 to 2 intervening carbon atoms, both aromatic rings being either unsubstituted or substituted by a hydroxyl group or a group converted in vivo to hydroxyl;

b) a side chain possessing an aromatic ring and a tertiary amine function or salt thereof;


and wherein said modulator is not a benzothiophene derivative, a phenylindole derivative, a napthalene derivative, an isoquinoline derivative or an enantiomeric mixture of 3-phenylquinoline derivatives, 3-pheynulthiochroman derivatives, and 3-phenylchroman derivatives having more than 10% of the enantiomer of 2R configuration.

**Claim 4 (Original)** The pharmaceutical composition of claim 3, wherein the side chain is selected from the group consisting of:



**Claim 5 (Original)** The pharmaceutical composition of claim 3, wherein the selective estrogen receptor modulator is selected from the group consisting of a triphenylethylene derivative, benzopyran derivative, HMR 3339, HMR 3656, LY 335124, LY 326315, SH 646, ERA 923 and centchroman derivative.

**Claim 6 (Withdrawn)** The pharmaceutical composition of claim 2, wherein the selective estrogen receptor modulator is a benzothiophene derivative compound of the following formula:



wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of : hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl ;


wherein R<sub>3</sub> and R<sub>4</sub> are either (a) independently C1-C4 alkyl, or (b) a moiety which in combination with the nitrogen to which they are bound, is selected from the group consisting of pyrrolidino, dimethyl-1- pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino and morpholino;

wherein A is selected from the group consisting of -CO-, -CHOH, and -CH<sub>2</sub>-;

wherein B is selected from the group consisting of phenylene, pyridylidene, and -cycloC<sub>4</sub>H<sub>2</sub>N<sub>2</sub>-.

Claim 7 (Withdrawn) The pharmaceutical composition of claim 6, wherein the selective estrogen receptor modulator is selected from the group consisting of Raloxifene, LY 353381 and LY 335563.

Claim 8 (Withdrawn) The pharmaceutical composition of claim 3, wherein the selective estrogen receptor modulator is a triphenylethylene or diphenylhydronaphthalene derivative compound of the following formula:




wherein D is  $-\text{OCH}_2\text{CH}_2\text{N}(\text{R}_3)\text{R}_4$ ,  $-\text{OCH}_2\text{CH}_2\text{OH}$ , or  $-\text{CH}=\text{CH}-\text{COOH}$  ( $\text{R}_3$  and  $\text{R}_4$  either being independently selected from the group consisting of C1-C4 alkyl, or  $\text{R}_3$ ,  $\text{R}_4$ , and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino and morpholino);

wherein E and K are independently hydrogen or hydroxyl, phosphate ester, or lower alkyl, wherein J is hydrogen or halogen.

**Claim 9 (Withdrawn)** The pharmaceutical composition of claim 3, wherein selective estrogen receptor modulator is OH-tamoxifen, Droloxifene, Toremifene, Iodoxifene, Lasofoxifene, iproxifene, FC 1271, and GW5638.

**Claim 10 (Withdrawn)** The pharmaceutical composition of claim 3, wherein the selective estrogen receptor modulator is a centchroman derivative compound of the following formula:




wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of : hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl;

wherein R<sub>5</sub> and R<sub>6</sub> are independently hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl ;

wherein D is -OCH<sub>2</sub>CH<sub>2</sub>N(R<sub>3</sub>)R<sub>4</sub> ( R<sub>3</sub> and R<sub>4</sub> either being independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, or R<sub>3</sub>, R<sub>4</sub> and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1- pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino, morpholino).

**Claim 11 (Withdrawn)** The pharmaceutical composition of claim 10, wherein the centchroman derivative is (3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-7-methoxychroman).

**Claim 12 (Currently amended)** The pharmaceutical composition of claim 3, wherein the selective estrogen receptor modulator has the following formula:



wherein  $R_1$  and  $R_2$  are independently hydrogen, hydroxyl or a moiety which is converted to hydroxyl in vivo;

wherein  $Z$  is either absent or selected from the group consisting of  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{S}-$  and  $-\text{NR}_3-$  ( $R_3$  being hydrogen or lower alkyl);

wherein the  $R_{100}$  is a bivalent moiety which distances  $L$  from the B-ring ring carbon to which  $R_{100}$  is attached by 4-10 intervening atoms;


wherein  $L$  is a bivalent or trivalent moiety selected from the group of  $-\text{SO}-$ ,  $-\text{CON}-$ ,  $-\text{N}^<$ , and  $-\text{SON}^<$ ;

wherein  $G_1$  is selected from the group consisting of hydrogen, a  $C_1$  to  $C_5$  hydrocarbon, a bivalent moiety which in combination with  $G_2$  and  $L$  is a 5-to 7- membered heterocyclic ring, and halo or unsaturated derivatives of the foregoing;

wherein  $G_2$  is either absent or selected from the group consisting of hydrogen, a  $C_1$  to  $C_5$  hydrocarbon, a bivalent moiety which in combination with  $G_1$  and  $L$  is a 5-to 7- membered heterocyclic ring, and halo or unsaturated derivatives of the foregoing;

wherein  $G_3$  is selected from the group consisting of hydrogen, methyl and ethyl.

Claim 13 (Currently amended) The pharmaceutical composition of claim 12, wherein the compound is a benzopyran derivative of the following general structure:




or a pharmaceutically acceptable salt thereof,

wherein D is  $-\text{OCH}_2\text{CH}_2\text{N}(\text{R}_3)\text{R}_4$  ( $\text{R}_3$  and  $\text{R}_4$  either being independently selected from the group consisting of  $\text{C}_1\text{-C}_4$  alkyl, or  $\text{R}_3$ ,  $\text{R}_4$  and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino, morpholino);

wherein  $\text{R}_1$  and  $\text{R}_2$  are independently selected from the group consisting of : hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl.

Claim 14 (Original) The pharmaceutical composition of claim 13, wherein the benzopyran derivative is optically active due to a majority of its stereoisomer having an absolute configuration S on carbon 2, said compound having the molecular structure:




wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of hydroxyl and a moiety convertible in vivo to hydroxyl;


wherein R<sup>3</sup> is a species selected from the group consisting of saturated, unsaturated or substituted pyrrolidinyl, saturated, unsaturated or substituted piperidino, saturated, unsaturated or substituted piperidinyl, saturated, unsaturated or substituted morpholino, nitrogen-containing cyclic moiety, nitrogen-containing polycyclic moiety, and NR<sub>a</sub>R<sub>b</sub> (R<sub>a</sub> and R<sub>b</sub> being independently hydrogen, straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl, straight or branched C<sub>2</sub>-C<sub>6</sub> alkenyl, and straight or branched C<sub>2</sub>-C<sub>6</sub> alkynyl).

Claim 15 (Original) The pharmaceutical composition of claim 14, wherein said compound or salt substantially lacks (2R)-enantiomer.


Claim 16 (Original) The pharmaceutical composition of claim 14, wherein said selective estrogen receptor modulator is selected from the group consisting of:




**EM-1900**




**EM-1901**




**EM-1903**



**EM-1533**




**EM-1518**



and

**EM-652.HCl**  
**(EM-1538)**




wherein all of the foregoing molecular structures whose stereochemistry is indicated are optically active due to a majority of their stereoisomers being of 2S configuration.

**Claim 17 (Original)** The pharmaceutical composition of claim 14, wherein the benzopyran derivative is a salt of an acid selected from the group consisting of acetic acid, adipic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, fumaric acid, hydroiodic acid, hydrobromic acid, hydrochloric acid, hydrochlorothiazide acid, hydroxy-naphthoic acid, lactic acid, maleic acid, methanesulfonic acid, methylsulfuric acid, 1,5-naphthalenedisulfonic acid, nitric acid, palmitic acid, pivalic acid, phosphoric acid, propionic acid, succinic acid, sulfuric acid, tartaric acid, terephthalic acid, p-toluenesulfonic acid, and valeric acid.

**Claim 18 (Original)** The pharmaceutical composition of claim 17, wherein the acid is hydrochloric acid.

**Claim 19 (Original)** The pharmaceutical composition of claim 1, wherein said selective estrogen receptor modulator is:

**EM-652.HCl**  
**(EM-1538)**



and is optically active due to a majority of its stereoisomers being of 2S configuration; and

wherein the estrogen is selected from the group consisting of 17 $\beta$ -estradiol, 17 $\beta$ -estradiol esters, 17 $\alpha$ -estradiol, 17 $\alpha$ -estradiol esters, estriol, estriol esters, estrone, estrone esters, conjugated estrogen, equilin, equilin esters, 17 $\alpha$ -ethynylestradiol, 17 $\alpha$ -ethynylestradiol esters, mestranol, and mestranol esters.

**Claim 20 (Original)** The pharmaceutical composition of claim 1, wherein said estrogen is selected from the group consisting of 17 $\beta$ -estradiol, 17 $\beta$ -estradiol esters, estriol, estriol esters, estrone, estrone esters, conjugated estrogen, equilin, equilin esters, 17 $\alpha$ -ethynylestradiol, 17 $\alpha$ -ethynylestradiol esters, mestranol, mestranol esters, chemestrogen, DES, phyttestrogen, tibolone, 2'-ethylestrogenoxazole, and ethynediol.

**Claim 21 (Withdrawn)** The pharmaceutical composition of claims 1, wherein said estrogen is a mixed estrogenic/androgenic compound.

**Claim 22 (Original)** A kit comprising a first container containing a pharmaceutical formulation comprising a therapeutically effective amount of at least one estrogen or a prodrug thereof; and said kit further comprising a second container containing a pharmaceutical formulation comprising a therapeutically effective amount of at least one selective estrogen receptor modulator or prodrug thereof, said modulator not being a benzothiophene or a phenylindole derivative.


**Claim 23 (Original)** A kit comprising a first container containing a pharmaceutical formulation comprising a therapeutically effective amount of at least one estrogen or a prodrug thereof; and said kit further comprising a second container containing a pharmaceutical formulation comprising a therapeutically effective amount of at least one selective estrogen receptor modulator or prodrug thereof, comprising at least one additional container of said kit that contains a therapeutically effective amount of at least one additional agent selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3 $\beta$ ,17 $\beta$ -diol, an androgenic agent, testosterone, 4-androstene-3,17-dione and a prodrug of any of the foregoing additional agents.

Claim 24 (Withdrawn) The kit of claim 22 further comprising at least one additional container containing a pharmaceutical formulation comprising a therapeutically effective amount of at least one bisphosphonate.

Claim 25 (Original) The kit of claims 22, wherein the selective estrogen receptor modulator has a molecular formula with the following features:


- a) two aromatic rings spaced by 1 to 2 intervening carbon atoms, both aromatic rings being either unsubstituted or substituted by a hydroxyl group or a group converted in vivo to hydroxyl;
- b) a side chain possessing an aromatic ring and a tertiary amine function or salt thereof; and wherein said modulator is not a benzothiophene derivative, a phenylindole derivative, a naphtalene derivative, an isoquinoline derivative or an enantiomeric mixture of 3-phenylquinoline derivatives, 3-pheynulthiochroman derivatives, 3-phenylchroman derivatives having more than 10% of the enantiomer of 2R configuration.

Claim 26 (Original) The kit of claim 25, wherein the side chain is selected from the group consisting of:



Claim 27 (Original) The kit of claim 25, wherein the selective estrogen receptor modulator is selected from the group consisting of a triphenylethylene derivative, benzopyran derivative, HMR 3339, HMR 3656, LY 335124, LY 326315, SH 646, ERA 923 and centchroman derivative.

Claim 28 (Withdrawn) The kit of claim 23, wherein the selective estrogen receptor modulator is a benzothiophene derivative compound of the following formula:



wherein  $R_1$  and  $R_2$  are independently selected from the group consisting of : hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl;


wherein  $R_3$  and  $R_4$  are either (a) independently C1-C4 alkyl, or (b) a moiety which in combination with the nitrogen to which they are bound, is selected from the group consisting of pyrrolidino, dimethyl-1- pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino and morpholino;

wherein  $A$  is selected from the group consisting of -CO-, -CHOH, and -CH<sub>2</sub>-;

wherein  $B$  is selected from the group consisting of phenylene, pyridylidene, and -cycloC<sub>4</sub>H<sub>2</sub>N<sub>2</sub>-.

Claim 29 (Withdrawn) The kit of claim 28, wherein the selective estrogen receptor modulator is selected from the group consisting of Raloxifene, LY 353381 and LY 335563.

Claim 30 (Withdrawn) The kit of claim 25, wherein the selective estrogen receptor modulator is a triphenylethylene or diphenylhydronaphthalene derivative compound of the following formula:




wherein D is  $-\text{OCH}_2\text{CH}_2\text{N}(\text{R}_3)\text{R}_4$ ,  $-\text{OCH}_2\text{CH}_2\text{OH}$ , or  $-\text{CH}=\text{CH}-\text{COOH}$  ( $\text{R}_3$  and  $\text{R}_4$  either being independently selected from the group consisting of C1-C4 alkyl, or  $\text{R}_3$ ,  $\text{R}_4$ , and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino and morpholino);

wherein E and K are independently hydrogen or hydroxyl, phosphate ester, or lower alkyl, wherein J is hydrogen or halogen.

Claim 31 (Withdrawn) The kit of claim 22, wherein selective estrogen receptor modulator is OH-tamoxifen, Droloxifene, Toremifene, Iodoxifene, Lasofoxifene, iproxifene, FC 1271, and GW5638.

Claim 32 (Withdrawn) The kit of claim 25, wherein the selective estrogen receptor modulator is a centchroman derivative compound of the following formula:




wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of : hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl;

wherein R<sub>5</sub> and R<sub>6</sub> are independently hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

wherein D is -OCH<sub>2</sub>CH<sub>2</sub>N(R<sub>3</sub>)R<sub>4</sub> ( R<sub>3</sub> and R<sub>4</sub> either being independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, or R<sub>3</sub>, R<sub>4</sub> and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1- pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino, morpholino).

**Claim 33 (Withdrawn)** The kit of claim 32, wherein the centchroman derivative is (3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-7-methoxychroman).

**Claim 34 (Currently amended)** The kit of claim 25, wherein the selective estrogen receptor modulator has the following formula:



wherein  $R_1$  and  $R_2$  are independently hydrogen, hydroxyl or a moiety which is converted to hydroxyl in vivo;

wherein  $Z$  is either absent or selected from the group consisting of  $-\text{CH}_2-$ ,  $-\text{O}-$ ,  $-\text{S}-$  and  $-\text{NR}_3-$  ( $R_3$  being hydrogen or lower alkyl);

wherein the  $R_{100}$  is a bivalent moiety which distances  $L$  from the B-ring ring carbon to which  $R_{100}$  is attached by 4-10 intervening atoms;


wherein  $L$  is a bivalent or trivalent moiety selected from the group of  $-\text{SO}-$ ,  $-\text{CON}-$ ,  $-\text{N}^<$ , and  $-\text{SON}^<$ ;

wherein  $G_1$  is selected from the group consisting of hydrogen, a  $C_1$  to  $C_5$  hydrocarbon, a bivalent moiety which in combination with  $G_2$  and  $L$  is a 5-to 7- membered heterocyclic ring, and halo or unsaturated derivatives of the foregoing;

wherein  $G_2$  is either absent or selected from the group consisting of hydrogen, a  $C_1$  to  $C_5$  hydrocarbon, a bivalent moiety which in combination with  $G_1$  and  $L$  is a 5-to 7- membered heterocyclic ring, and halo or unsaturated derivatives of the foregoing;

wherein  $G_3$  is selected from the group consisting of hydrogen, methyl and ethyl.

Claim 35 (Currently amended) . . . The kit of claim 34, wherein the compound is a benzopyran derivative of the following general structure:




or a pharmaceutically acceptable salt thereof,

wherein D is  $-\text{OCH}_2\text{CH}_2\text{N}(\text{R}_3)\text{R}_4$  ( $\text{R}_3$  and  $\text{R}_4$  either being independently selected from the group consisting of  $\text{C}_1\text{-C}_4$  alkyl, or  $\text{R}_3, \text{R}_4$  and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino and morpholino);

wherein  $\text{R}_1$  and  $\text{R}_2$  are independently selected from the group consisting of : hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl.

**Claim 36 (Original)** The kit of claim 35, wherein the benzopyran derivative is optically active due to a majority of its stereoisomer having an absolute configuration S on carbon 2, said compound having the molecular structure:




wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of hydroxyl and a moiety convertible in vivo to hydroxyl;


wherein R<sup>3</sup> is a species selected from the group consisting of saturated, unsaturated or substituted pyrrolidinyl, saturated, unsaturated or substituted piperidino, saturated, unsaturated or substituted piperidinyl, saturated, unsaturated or substituted morpholino, nitrogen-containing cyclic moiety, nitrogen-containing polycyclic moiety, and NR<sub>a</sub>R<sub>b</sub> (Ra and Rb being independently hydrogen, straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl, straight or branched C<sub>2</sub>-C<sub>6</sub> alkenyl, and straight or branched C<sub>2</sub>-C<sub>6</sub> alkynyl).

**Claim 37 (Original)** The kit of claim 36, wherein said compound or salt substantially lacks (2R)-enantiomer.


**Claim 38 (Original)** The kit of claim 36, wherein said selective estrogen receptor modulator is selected from the group consisting of:




**EM-1900**




**EM-1901**




**EM-1903**



**EM-1533**




**EM-1518**



and

**EM-652.HCl**  
**(EM-1538)**




wherein all of the foregoing molecular structures whose stereochemistry is indicated are optically active due to a majority of their stereoisomers being of 2S configuration.

**Claim 39 (Original)** The kit of claim 36, wherein the benzopyran derivative is a salt of an acid selected from the group consisting of acetic acid, adipic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, fumaric acid, hydroiodic acid, hydrobromic acid, hydrochloric acid, hydrochlorothiazide acid, hydroxy-naphthoic acid, lactic acid, maleic acid, methanesulfonic acid, methylsulfuric acid, 1,5-naphthalenedisulfonic acid, nitric acid, palmitic acid, pivalic acid, phosphoric acid, propionic acid, succinic acid, sulfuric acid, tartaric acid, terephthalic acid, p-toluenesulfonic acid, and valeric acid.

**Claim 40 (Original)** The kit of claim 39, wherein the acid is hydrochloric acid.

**Claim 41 (Original)** The kit of claim 22, wherein said selective estrogen receptor modulator is:

**EM-652.HCl**  
**(EM-1538)**



and is optically active due to a majority of its stereoisomers being of 2S configuration; and

wherein the estrogen is selected from the group consisting of 17 $\beta$ -estradiol, 17 $\beta$ -estradiol esters, 17 $\alpha$ -estradiol, 17 $\alpha$ -estradiol esters, estriol, estriol esters, estrone, estrone esters, conjugated

estrogen, equilin, equilin esters, 17 $\alpha$ -ethynylestradiol, 17 $\alpha$ -ethynylestradiol esters, mestranol, and mestranol esters.

Claim 42 (Original) The kit of claim 22, wherein said estrogen is selected from the group consisting of 17 $\beta$ -estradiol, 17 $\beta$ -estradiol esters, estriol, estriol esters, estrone, estrone esters, conjugated estrogen, equilin, equilin esters, 17 $\alpha$ -ethynylestradiol, 17 $\alpha$ -ethynylestradiol esters, mestranol, mestranol esters, chemestrogen, DES, phyttestrogen, tibolone, 2'-ethylestrogenoxazole, and ethynediol.

Claim 43 (Original) The kit of claim 22, wherein said estrogen is a mixed estrogenic/androgenic compound.